EMA/401553/2023

European Medicines Agency decision

P/0441/2023

of 27 October 2023

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for luspatercept (Reblozyl), (EMEA-001521-PIP03-22) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0441/2023

of 27 October 2023

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for luspatercept (Reblozyl), (EMEA-001521-PIP03-22) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Bristol-Myers Squibb Pharma EEIG on 26 May 2022 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 8 September 2023, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

(4) It is therefore appropriate to adopt a decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

A paediatric investigation plan for luspatercept (Reblozyl), powder for solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for luspatercept (Reblozyl), powder for solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for luspatercept (Reblozyl), powder for solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision covers all conditions, indications, pharmaceutical forms, routes of administration, measures, timelines, waivers and deferrals, as agreed in the decision P/0245/2014 issued on 29 September 2014, including subsequent modifications thereof.

Article 5

This decision is addressed to Bristol-Myers Squibb Pharma EEIG, Plaza 254, Blanchardstown Corporate Park 2, D15 T867 - Dublin 15, Ireland.

EMA/PDCO/264801/2023
Amsterdam, 8 September 2023

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMEA-001521-PIP03-22

Scope of the application

Active substance(s):

Luspatercept

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of alpha-thalassaemia

Pharmaceutical form(s):

Powder for solution for injection

Route(s) of administration:

Subcutaneous use

Name/corporate name of the PIP applicant:

Bristol-Myers Squibb Pharma EEIG

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Bristol-Myers Squibb Pharma EEIG submitted for agreement to the European Medicines Agency on 26 May 2022 an application for a paediatric investigation plan for the above-mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 11 July 2022.

Supplementary information was provided by the applicant on 25 May 2023. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
   - to grant a deferral in accordance with Article 21 of said Regulation;
   - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(a) of said Regulation, on the grounds that the specific medicinal product is likely to be ineffective or unsafe in part or all of the paediatric population.

   The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of alpha-thalassaemia

The waiver applies to:

- the paediatric population from birth to less than 6 years of age;
- powder for solution for injection, subcutaneous use;
- on the grounds that the specific medicinal product is likely to be unsafe.

2. Paediatric investigation plan

2.1. Condition:

Treatment of alpha-thalassaemia

2.1.1. Indication(s) targeted by the PIP

Treatment of anaemia in paediatric patients with alpha-thalassemia haemoglobin H disease

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 years to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Powder for solution for injection

2.1.4. Measures

Area	**Description**
Quality-related studies	Not applicable
Non-clinical studies	Not applicable
Clinical studies	**Study 1** Study with an open-label cohort to evaluate pharmacokinetics, safety and activity of luspatercept in paediatric patients from 12 years to less than 18 years of age with alpha-thalassemia haemoglobin H (HbH) disease (adolescent cohort as part of the adult study CA056-015). **Study 2** Double-blind, randomised, placebo-controlled trial to evaluate safety and efficacy of luspatercept in paediatric patients from 6 years to less than 12 years of age with alpha-thalassemia HbH disease.

Modelling and simulation studies	**Study 3** Modelling and simulation study to describe luspatercept serum exposure data and factors associated with the exposure variability in children from 6 years to less than 18 years of age with alpha-thalassemia HbH disease.
Other studies	Not applicable
Extrapolation plan	Study 1 (CA056-015; data from adults and adolescents) is part of an extrapolation plan covering the paediatric population from 12 years to less than 18 years of age, as agreed by the PDCO.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By May 2030
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

Condition(s) and authorised indication(s)

1. Treatment of myelodysplastic syndromes

Authorised indication(s):

- Treatment of adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy.
  - Invented name(s): Reblozyl
  - Authorised pharmaceutical form(s): Powder for solution for injection
  - Authorised route(s) of administration: Subcutaneous use
  - Authorised via centralised procedure

2. Treatment of beta-thalassaemia

Authorised indication(s):

- Treatment of adult patients with anaemia associated with transfusion-dependent and non-transfusion-dependent beta-thalassaemia.
  - Invented name(s): Reblozyl
  - Authorised pharmaceutical form(s): Powder for solution for injection
  - Authorised route(s) of administration: Subcutaneous use
  - Authorised via centralised procedure